v3.26.1
COLLABORATION AND RESEARCH AGREEMENTS (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 16, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Operating expenses   $ 4,563 $ 2,668 $ 8,102 $ 5,231
2025 Collaboration Agreement with OPKO [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, nature and purpose Company and OPKO have agreed to collaborate with respect to the preclinical and clinical development and decision making related to the oral delivery of a dual agonist GLP-1/glucagon peptide in an oral dosage form using Entera’s N-Tab™ technology platform for the treatment of obesity, metabolic and fibrotic disorders in humans. The Company and OPKO share in the economics and development costs of such program at 40% and 60%, respectively, subject to certain opt-out provisions.        
Number of ordinary shares issued 3,685,226        
Purchase price of ordinary shares $ 8,000        
Operating expenses   $ 641   $ 1,164